• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
RXRX

RXRX

Recursion Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.47

-0.14 (-3.88%)

Rating:C

Company Profile

CEO

Najat Khan

IPO Date

2021-04-16

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.54

Prev. Close

$3.61

Day Low

$3.37

Day High

$3.54

52W Low

$2.77

52W High

$7.18

Market Cap

$1.55B

Volume

18.29M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

9

Avg Positive

45.8%

Avg Negative

24.9%

Avg Neutral

29.3%

News Feed

Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD

PRNewsWire·7/13/2021·↑ positive

Recursion Opens Child Care Center to Support Employees

PRNewsWire·7/12/2021·↓ negative

Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City

PRNewsWire·7/1/2021·↑ positive

Got $2,500? Check Out These 2 Biotech 2.0 Stocks

The Motley Fool·7/1/2021·↓ negative

Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery

PRNewsWire·6/23/2021·↑ positive

Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery

PRNewsWire·6/15/2021·↑ positive

Losers Outnumber Gainers in Biotech IPOs This Year

GuruFocus·6/1/2021·↓ negative

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis

PRNewsWire·5/25/2021·↑ positive

2 Hot Biotech IPOs to Consider

The Motley Fool·4/27/2021·↑ positive